VTAK
Catheter Precision·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
VTAK Profile
Catheter Precision, Inc.
A commercial grade medical device company
Healthcare Equipment and Supplies
--
12/28/2020
American Stock Exchange
22
12-31
Common stock
1670 Highway 160 West – Suite 205, Fort Mill, South Carolina 29708
--
Catheter Precision, Inc., was incorporated in Delaware in July 2018 and was previously incorporated in California on September 4, 2002. The company is a commercial-stage medical device company utilizing advanced excimer laser-based platforms for the treatment of vascular and skin diseases. The company believes that products improve patients' quality of life by restoring arterial blood flow and clearing chronic skin conditions. DABRA is approved by the US Food and Drug Administration (FDA) as a minimally invasive endovascular treatment tool for vascular blockages caused by lower extremity vascular disease, including peripheral arterial disease or PAD, which often occurs in the legs. Ra Medical Systems intends to pursue the use of DABRA, including seeking regulatory approval for the use of DABRA as a tool for the treatment of vascular blockages associated with coronary artery disease or CAD, in-stent restenosis, venous and arterial blockages, or venous or arterial blockages. The DABRA laser system is based on the same core technology and uses an excimer laser similar to PharOS, a medical device that the company has been marketing as a tool for the treatment of proliferative skin conditions since October 2004. Pharos is designed for the treatment of inflammatory skin conditions and is approved by the FDA as a tool for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. Since both DABRA and PHAROS are based on their core excimer laser technology platforms and deploy similar mechanisms of action, they benefit from economies of scale in product development, manufacturing, quality assurance and distribution.
